|View printer-friendly version|
The two-day event will highlight strategies for delivering drugs to patients faster
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005512/en/
We can’t get drugs to the clinic faster simply by throwing money at the problem. Accelerating the process from concept to cure is going to require the brightest minds, the boldest approaches, and combined efforts toward a common goal. Are you up for the challenge?
Voices of Drug Discovery
Featured speakers include:
Timothy Yu, M.D., Ph.D., Attending Physician, Division of Genetics and Genomicsat Boston Children’s Hospital, Associate Member of the Broad Institute, and Assistant Professor in Pediatrics at Harvard Medical School, will discuss the accelerated development of milasen as an example of truly individualized genomic medicine. Allyson Berent, DVM, DACVIM, Chief Operating Officer of GeneTx Biotherapeutics and Chief Science Officer of the Foundation for Angelman Syndrome Therapeutics, will share her personal journey from veterinary specialist to CSO of a non-profit and co-founder of a biotherapeutic company when her infant daughter was diagnosed with a random, rare, neurogenetic disorder called Angelman syndrome.
Charles River Annual Research Award
Previous winners of the Annual Research Award include Sonia Vallabah and
September 23-24, 2019
Kimpton Marlowe, Cambridge, Mass.
- Charitable Giving: Charles River will donate 100% of every World
Congressregistration fee to the Amyotrophic Lateral Sclerosis Therapy Development Institute, a Cambridge-based nonprofit biotech dedicated to finding a cure for ALS.
- Registration: To learn more and register, visit criver.com/worldcongress
- Join the Conversation: Follow #CRLworldcon on social media
“Developing therapeutics is a long and complex process. The average drug spends 10 years in development—we simply have to do better for patients. Our goal with this year’s
World Congressis to inspire researchers to think outside of how we’ve historically developed drugs and implement innovative strategies to save time and money.” –James C. Foster, Chairman, President and Chief Executive Officer, Charles River
“The Grace Science team has researched, recruited, and assembled a global team of 200 researchers and clinicians across 18 international centers over the last 5 years. We are constantly looking to fill gaps and improve, but we believe the breadth and depth of our global network is unique. We are proud to accept the Charles River Annual Research Award. With these funds, we will be able to propel our research and therapies even further and faster.” –Matt Wilsey, Chairman,
President & Co-founderof the Grace Science Foundation
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Corporate Vice President, Investor Relations
Corporate Vice President, Public Relations